|
Илтгэлүүд
1.0.1.Scope and purpose
1.0.2.Provisional agenda
1.0.3.Participants
1.1.1.Introduction and Objectives, Wenqing Zhang, GIP WHO
1.1.2.Strategies on Influenza: Global Influenza Programme Perspective, Sylvie Briand, GIP WHO
1.1.3.Report of progress since 2nd NIC meeting, Wenqing Zhang, GIP WHO
Session A: GISN response to pandemic 2009
1.2.1.A review from WHO HQ, Niteen Wairagkar, GIP WHO
1.2.2.A review from WHO CCs, Alexander Klimov, WHOCC, US
1.2.3.Pandemic Response AMRO/A review from AMR, Otavio Oliva, AMRO WHO
1.2.4.A review from EUR, Caroline Brown, EURO WHO
1.2.5.A review from SEAR, Rajesh Bhatia, SEARO WHO
A review from NIC Japan, Takato Odagiri, Japan
Session B: GISN capacity in general
1.3.1.Preliminary results from global NIC survey 2010, Rodrigo Fasce, GIP WHO
1.3.2.Results from antiviral-sequencing survey, Helena Rebelo de Andrade, GIP WHO
1.3.3.AFR, Ali Yahaya, AFRO WHO
1.3.4.EMR, Hassan El Bushra, EMRO WHO
1.3.5.WPR, Jeffrey Partridge, WPRO WHO
1.3.6.NIC Cameroon, Richard Njouom, Cameroon
1.3.7.NIC Cuba, Betsy Acosta, Cuba
1.3.8.NIC Sri Lanka, Geethani Wickramasinghe, Sri Lanka
1.3.9.NIC Tunisia, Aouatef El Moussi, Tunisia
Session C: Strategic directions of GISN development
2.1.1.Strategic directions of GISN development at global level, Wenqing Zhang, GIP WHO
2.1.2.AFR, Ali Yahaya, AFRO WHO
2.1.3.EUR, Caroline Brown, EURO WHO
2.1.4.NIC Argentina, Vilma Savy, Argentina
2.1.5.NIC Mongolia, Pagbajab Nymadawa, Mongolia
2.2.1.Strategic directions of development of global epidemiological/disease surveillance, Anthony Mounts, GIP WHO
2.2.2.Current status and future development of CDC bilateral Cooperative Agreements, Ann Moen, WHOCC, US
2.2.3.NIH global surveillance activities and future development
2.2.4.Current status and future development of Pasteur Institute Network, Sylvie Van der Werf, PI France
2.2.5.OFFLU strategy on surveillance of influenza in animals, Keith Hamilton, OFFLU, France
Session D: GISN development, more timeliness
2.3.01.A view from WHO CCs, Rod Daniels, WHOCC, UK
2.3.02.A view from NIC Madagascar, Jean-Michel Héraud, Madagascar
2.3.03.GISN reporting, Maja Lièvre, GIP WHO
Session E: GISN development, better quality
2.3.04.A view from WHO CCs, Xiyan Xu, WHOCC, US
2.3.05.A view from NIC HK, Wilina Lim, HK China
2.3.06.Review of EQAP on using PCR and reflection of other QA/QC activities, Terry Besselaar, GIP WHO
Session F: GISN development, closer linking GISN output to public health products
2.3.07.A view from WHO, Wenqing Zhang, GIP WHO
2.3.08.A view from MoH, Xiao Donglou, China
2.3.09.A view from India, Jagvir Singh, India
2.3.10.A view from Tunisia, Amine Slim, Tunisia
Session G: GISN development, higher efficiency
3.1.1.A view from WHO CCs, Ian Barr, WHOCC, Australia
3.1.2.A view from China, Dayan Wang, WHOCC, China
3.1.3.A review of the WHO Shipment Fund Project and other logistics efforts, Christian Fuster, GIP WHO
Session H: GISN development, developing partnership
3.2.1.USAID on influenza surveillance and control, Robert Blanchard, USAID US
3.2.2.IFPMA on GISN development and vaccine Production, Tony Colgate, IFPMA, UK
3.2.3.BRADA on GISN and influenza, Rick Bright, BARDA, US
Session I: GISN communication and other topics
3.3.1.Summary of communication issues from NIC Survey, Rodrigo Fasce, GIP WHO
3.3.2.Update from WHOCC CDC Atlanta on IRR development, Mary Hoelscher, WHOCC US
Working groups
4.1.1.WG 1: GISN experience and lessons learnt from response to thepandemic A(H1N1) 2009
4.1.2.WG 2: GISN development: more timeliness
4.1.3.WG 3: GISN development: better quality
4.1.4.WG 4: GISN development: higher efficiency
4.1.5.WG 5: GISN development: closer linking to public health products
4.1.6.WG 6: GISN development: developing partnership
Supplements
suppl.01. Meeting with NICS Barcelona2008.pdf
suppl.02. Meeting of working group for PCR WER8546.pdf
suppl.03. Selection on clinical specimens for PCR, virus isolation and shipment for NICs.pdf
suppl.04. PandemicContingencyPlanning.pdf
suppl.05. Instructions for storage and transport of suspected or confirmed human.pdf
suppl.06. Laboratorybioriskmanagement.pdf
suppl.07. Availability of a candidate international standard.pdf
suppl.08. Summary of status of cvv and potency reagents.pdf
suppl.09. Global influenza surveillance network WER8436.pdf
suppl.10. Recommended viruses for influenza vaccines for use in the 2011 southern hemisphere influenza season.pdf
2.3.03.GISN reporting, Maja Lièvre, GIP WHO
suppl.11. Antigenic and genetic characteristics H5-H9 wer8542.pdf
suppl.12. Preliminary review of D222G substitution wer8504.pdf
suppl.13. WHO EQAP summary analysis 2009 WER48.pdf
suppl.14. Epidemiological, antigenic and genetic characteristics Vaccine 28 (2010).pdf
suppl.15. Pandemic Influenza Preparedeness, outcome of the results of IGM.pdf
suppl.16. How to register to the GISN EZcollab.pdf
suppl.17. Influenza update - 22 November 2010.pdf
suppl.18. Influenza update - 22 November 2010.pdf
suppl.19. Northern_fluNet_graphs_week_01_to_44.pdf
suppl.20. Guidance_Shipment_fund_project_2010.pdf
suppl.21. Cover page and index LabManual.draft.pdf
suppl.22. Operational Framework NIC activities during WHO Pandemic Phases 5-6 DRAFT.pdf
suppl.23. Improving influenza vaccine virus selection.pdf
suppl.24. RoleofNICsinmonitoring.draft.pdf
suppl.25. Serological diagnosis of Influenza CDC Microneut method.draft.pdf
suppl.26. WHO EQAP summary analysis, 2010 for WER.draft.pdf
Ханын илтгэлүүд
|
